A Court Decision on "Skinny Labeling": Another Challenge for Less Expensive Drugs

JAMA. 2021 Oct 12;326(14):1371-1372. doi: 10.1001/jama.2021.0006.

Authors

Bryan S Walsh^{1

2}, Doni Bloomfield^{1

2}, Aaron S Kesselheim^{1

2}

Affiliations

¹ Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
² Harvard Medical School Center for Bioethics, Boston, Massachusetts.

PMID: 34515733
DOI: 10.1001/jama.2021.0006

No abstract available

MeSH terms

Drug Labeling / legislation & jurisprudence*
Drugs, Generic* / economics
Legislation, Drug
Patents as Topic*
Pharmaceutical Preparations / economics
Therapeutic Equivalency
United States
United States Food and Drug Administration

Substances

Drugs, Generic
Pharmaceutical Preparations